Carna Biosciences, Inc. (TYO:4572)

Japan · Delayed Price · Currency is JPY

400.00

-9.00 (-2.20%)

Aug 27, 2026, 1:14 PM JST

76.21% (1Y)

Market Cap	8.65B +99.5%
Revenue (ttm)	729.00M +27.4%
Net Income	-2.15B
EPS	-111.33
Shares Out	21.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,200
Open	411.00
Previous Close	409.00
Day's Range	397.00 - 413.00
52-Week Range	200.00 - 512.00
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 61

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4572

Full Company Profile

Financial Performance

In 2025, Carna Biosciences's revenue was 579.00 million, a decrease of -8.96% compared to the previous year's 636.00 million. Losses were -2.17 billion, -0.32% less than in 2024.

Financial Statements